COMPANY




News Releases


Archives
  • 2004
  • 2002 - 2003
  • 2000 - 2001
  • 1998 - 1999
  • Phase II STS Certification

    Minneapolis, MN - March 10, 2000 - Velos Medical Informatics, Inc. today announced that its Velos Cardiology and Cardiothoracic Surgery information system has successfully concluded Phase II certification by the Society of Thoracic Surgeons (STS) and is now fully STS certified. Velos Cardiology and Cardiothoracic Surgery is a scalable information system designed to meet a wide range of customer needs in the cardiovascular market.

    ”STS Phase II certification brings us into full compliance with both the STS and American College of Cardiology (ACC) database specifications,” said John McIlwain, CEO. “STS customers will now be able to calculate Risk Stratification values to enhance both patient care and outcomes reporting. We believe that the Velos Cardiology and Cardiothoracic Surgery product currently provides powerful reporting, flexible interfacing and customization, and general ease of use. The implementation of the STS Risk Algorithms makes our product an even more complete solution.”

    Velos designs, develops and markets a comprehensive suite of software products and services that addresses the information processing needs of healthcare providers in the Cardiology, Renal, Transplantation, Oncology specialties, and for Enterprise healthcare use. Velos’ component-based, intranet/internet-ready suite of products and services supports patient care, clinical research, specialty procedures, scheduling, charge capture/compliance, medical billing/costing, and database integration. Velos’ web site is located at http://www.velos.com

    This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including the anticipated benefits resulting from STS Phase II certification. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.